The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

Diabetes-related foot ulcers (DFUs) and their sequelae result in large patient and societal burdens.

Using existing data from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, the researchers conducted post hoc analyses assessing the impact of liraglutide versus placebo in people with type 2 diabetes and at high risk of cardiovascular (CV) events on the incidence of DFUs and their sequelae.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Liraglutide.

The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.

Running at several centres spread the Liraglutide study over different clinics and patient groups.

Information on DFUs was collected systematically during the trial, and DFU complications were assessed post hoc through reviewing case narratives.

What Was Measured

The subject headings attached to it are Amputation, Surgical, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Foot, Hypoglycemic Agents and Liraglutide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Diabetes care), a journal based in United States.

More context: the Liraglutide compound page.